These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. T cells, particularly activated CD4 Wang Z; Chimenti MS; Strouse C; Weiner GJ Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453 [TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells. Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561 [TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493 [TBL] [Abstract][Full Text] [Related]
6. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer. Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406 [TBL] [Abstract][Full Text] [Related]
7. Increased TIGIT expressing NK cells with dysfunctional phenotype in AML patients correlated with poor prognosis. Liu G; Zhang Q; Yang J; Li X; Xian L; Li W; Lin T; Cheng J; Lin Q; Xu X; Li Q; Lin Y; Zhou M; Shen E Cancer Immunol Immunother; 2022 Feb; 71(2):277-287. PubMed ID: 34129052 [TBL] [Abstract][Full Text] [Related]
8. Short Communication: Metformin Reduces CD4 T Cell Exhaustion in HIV-Infected Adults on Suppressive Antiretroviral Therapy. Shikuma CM; Chew GM; Kohorn L; Souza SA; Chow D; SahBandar IN; Park EY; Hanks N; Gangcuangco LMA; Gerschenson M; Ndhlovu LC AIDS Res Hum Retroviruses; 2020 Apr; 36(4):303-305. PubMed ID: 31731885 [TBL] [Abstract][Full Text] [Related]
10. CD155/TIGIT, a novel immune checkpoint in human cancers (Review). Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677 [TBL] [Abstract][Full Text] [Related]
12. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126 [TBL] [Abstract][Full Text] [Related]
13. A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Vargas-Inchaustegui DA; Demberg T; Robert-Guroff M Immunology; 2011 Nov; 134(3):326-40. PubMed ID: 21978002 [TBL] [Abstract][Full Text] [Related]
14. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. Brauneck F; Seubert E; Wellbrock J; Schulze Zur Wiesch J; Duan Y; Magnus T; Bokemeyer C; Koch-Nolte F; Menzel S; Fiedler W Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884723 [TBL] [Abstract][Full Text] [Related]
15. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Ndhlovu LC; Lopez-Vergès S; Barbour JD; Jones RB; Jha AR; Long BR; Schoeffler EC; Fujita T; Nixon DF; Lanier LL Blood; 2012 Apr; 119(16):3734-43. PubMed ID: 22383801 [TBL] [Abstract][Full Text] [Related]
16. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047 [TBL] [Abstract][Full Text] [Related]
17. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells. Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM Front Immunol; 2021; 12():641521. PubMed ID: 33796107 [TBL] [Abstract][Full Text] [Related]
18. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56 Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K Front Immunol; 2021; 12():640672. PubMed ID: 34017328 [TBL] [Abstract][Full Text] [Related]
19. The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56 Ziegler AE; Fittje P; Müller LM; Ahrenstorf AE; Hagemann K; Hagen SH; Hess LU; Niehrs A; Poch T; Ravichandran G; Löbl SM; Padoan B; Brias S; Hennesen J; Richard M; Richert L; Peine S; Oldhafer KJ; Fischer L; Schramm C; Martrus G; Bunders MJ; Altfeld M; Lunemann S Front Immunol; 2023; 14():1117320. PubMed ID: 36845105 [TBL] [Abstract][Full Text] [Related]
20. PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions. Esen F; Deniz G; Aktas EC Immunol Lett; 2021 Dec; 240():15-23. PubMed ID: 34599946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]